Therapeutic treatment

Abstract

A combination comprising candesartan and rosuvastatin for the prevention or treatment of atherosclerosis and for the prevention of cardiovascular events is described.

1 - 11 . (canceled) 
     
     
         12 . A method of preventing or reducing the risk of cardiovascular events in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a combination comprising candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof. 
     
     
         13 . The method of  claim 12  wherein the combination is administered in association with a pharmaceutically acceptable diluent or carrier. 
     
     
         14 . A method of preventing or reducing the risk of cardiovascular events in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a combination consisting essentially of candesartan or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof as the sole therapeutically effective agents, and optionally a diuretic which is hydrochlorothiazide. 
     
     
         15 . The method of  claim 14  wherein the combination is administered in association with a pharmaceutically acceptable diluent or carrier. 
     
     
         16 . The method of  claim 14  wherein the composition is in the form of a single oral formulation. 
     
     
         17 . The method of any one of  claims 12 - 15  wherein candesartan is administered in the form of candesartan cilexetil. 
     
     
         18 . The method of any one of  claims 12 - 15  wherein the cardiovascular event is selected from myocardial infarction, worsening of angina, cardiac arrest, stroke, congestive heart failure and cardiovascular death.